liposomal doxorubicin + cyclophosphamide

Liposomal doxorubicin + cyclophosphamide is a combination chemotherapy regimen primarily used for the treatment of metastatic breast cancer and other solid tumors. Liposomal doxorubicin is an anthracycline antibiotic encapsulated in liposomes, which helps reduce cardiotoxicity and prolongs circulation time compared to conventional doxorubicin. It works by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage, inhibition of cell proliferation, and induction of apoptosis[5][6]. Cyclophosphamide is an alkylating agent that interferes with the growth of cancer cells by cross-linking DNA strands, resulting in cell death[7]. This combination has demonstrated efficacy as first-line therapy for metastatic breast cancer with a favorable safety profile compared to standard regimens[1][2].

Brand names

MyocetCaelyx

Other names

pegylated liposomal doxorubicin